ASCO – Lung Cancer | Physician's Weekly
Advertisement

ASCO – Lung Cancer

Phase II Keynote-799 Offers Promise for Stage IIA-C NSCLC

Results from the phase 2 Keynote-799 trial show that addition of pembrolizumab to concurrent chemoradiation in patients with unresectable, stage IIIA-C NSCLC leads to objective response rates (ORR) that exceeded 50%, researchers...

Nivolumab and Chemo Significantly Improved Survival in ES-SCL

In the phase 2 ECOG-ACRIN EA5161 trial, a significant improvement in both progression-free and overall survival was observed from adding the checkpoint inhibitor nivolumab to chemotherapy (cisplatin/carboplatin with etoposide)...

Loading

Advertisement

For latest news and updates
Email-id is invalid

Meeting Coverage